Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion

American Journal of Ophthalmology
Simon D M ChenC K Patel

Abstract

To evaluate the safety and efficacy of intravitreal triamcinolone acetonide (IVTA) for ischemic macular edema associated with branch retinal vein occlusion (BRVO) and foveal ischemia. Prospective interventional case series. setting: Clinical practice. study population: Eighteen eyes of 18 patients with macular edema associated with BRVO and foveal ischemia. intervention: Four mg IVTA. main outcome measures: Visual acuity (VA), optical coherence tomography, macular thickness measurements, and treatment-related complications. The mean duration of BRVO before treatment was 14 months. All patients were followed for a minimum of nine months, and 12 patients completed 12 months follow-up. The mean logarithm of the minimum angle of resolution (logMAR) VA improved significantly from 0.81 +/- 0.36 at baseline to 0.65 +/- 0.30 at one month (P = .03) but did not vary significantly from baseline at three, six, nine, and 12 months. Macular thickness improved significantly in all eyes from a mean of 400 +/- 134 mum preinjection, to 228 +/- 58 mum at one month (P < .01) and 256 +/- 121 mum at three months (P < .01) but did not vary significantly from baseline at six, nine, and 12 months. Eight eyes developed posterior subcapsular cataract, in...Continue Reading

References

Mar 1, 1984·The British Journal of Ophthalmology·J S Shilling, C A Jones
Sep 15, 1984·American Journal of Ophthalmology·A Patz
Jun 1, 1981·American Journal of Ophthalmology·B W McCuenR Machemer
Aug 1, 1980·Australian Journal of Ophthalmology·D V GreerR L Cooper
Apr 1, 1996·Ophthalmology·A Glacet-BernardM M Samama
Mar 29, 2001·Clinical & Experimental Ophthalmology·S YoungS Lightman
Sep 1, 2001·American Journal of Ophthalmology·J B Jonas, A Söfker
Jan 30, 2002·The British Journal of Ophthalmology·Paul B GreenbergElias Reichel
May 3, 2002·Ophthalmology·Adam MartidisCaroline Baumal
Jan 14, 2003·Archives of Ophthalmology·Jost B JonasRobert F Degenring
Jan 29, 2003·Journal of Cataract and Refractive Surgery·Mandi D ConwayGholam A Peyman
Feb 5, 2003·American Journal of Ophthalmology·Nathanael BenhamouAlain Gaudric
Feb 25, 2003·The British Journal of Ophthalmology·R F Degenring, J B Jonas
Jul 16, 2003·Acta Ophthalmologica Scandinavica·Robert F DegenringJost B Jonas
Jul 31, 2003·American Journal of Ophthalmology·Jost B JonasRobert F Degenring
Sep 10, 2003·Archives of Ophthalmology·Daniel B RothNauman A Chaudhry
Nov 5, 2003·American Journal of Ophthalmology·Darius M MoshfeghiWilliam F Mieler
Dec 4, 2003·Acta Ophthalmologica Scandinavica·Murat KaracorluSerra Karacorlu
Feb 11, 2004·Archives of Ophthalmology·Jost B JonasRobert F Degenring
Mar 10, 2004·Archives of Ophthalmology·Mark C GilliesAlex B L Hunyor
Mar 20, 2004·Journal of Cataract and Refractive Surgery·Jack T Holladay

❮ Previous
Next ❯

Citations

Dec 23, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Yasuaki HataTatsuro Ishibashi
Jun 12, 2008·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Eun Jee ChungHyoung Jun Koh
Aug 19, 2008·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Juliane RieseHeinrich Gerding
Feb 22, 2011·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Siamak MoradianMohammad Riazi Esfahani
Nov 19, 2011·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Masafumi OtaNagahisa Yoshimura
Feb 15, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Alireza RamezaniMehdi Yaseri
Jul 12, 2011·Japanese Journal of Ophthalmology·Kayoko TsukadaNagahisa Yoshimura
Sep 7, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Suk H ByeonOh W Kwon
Dec 15, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Soon Il KwonIn Won Park
May 17, 2007·The British Journal of Ophthalmology·Masafumi OtaNagahisa Yoshimura
Feb 11, 2014·International Journal of Clinical Pharmacy·Mehmet DemirSonmez Cinar
Feb 23, 2008·Current Eye Research·Jiri Rehak, Matus Rehak
Jun 19, 2013·Survey of Ophthalmology·Weerawat KiddeeYvonne M Buys
May 24, 2011·Survey of Ophthalmology·Justis P Ehlers, Sharon Fekrat
Oct 31, 2009·American Journal of Ophthalmology·John J WroblewskiChristine R Gonzales
May 25, 2010·Journal of Thrombosis and Haemostasis : JTH·M Rehak, P Wiedemann
Jul 13, 2012·Expert Opinion on Pharmacotherapy·Daniel F Kiernan, William F Mieler
Nov 30, 2007·American Journal of Ophthalmology·Masafumi OtaNagahisa Yoshimura
Jan 14, 2012·British Journal of Hospital Medicine·Amy-Lee ShirodkharSimon R J Taylor
Apr 12, 2018·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Young Hee YoonSusan Simonyi
Jun 1, 2008·Clinical Ophthalmology·Pier E Gallenga, Lucio Lobefalo
Jan 1, 2009·Journal of Ophthalmic & Vision Research·Siamak Moradian, Ramin Nourinia
Apr 22, 2009·Current Opinion in Ophthalmology·Thomas A Ciulla, Philip J Rosenfeld

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.